Chrysos delivers record FY26 results as PhotonAssay rollout gains pace
AI Market Summary
ASX-listed Chrysos reported record FY26 results with revenue up 33% to US$88.1m and EBITDA up 68% to US$27.2m, hitting the top end of guidance as margins expanded to 31%. Sample volumes rose 67% to 11.3m, and operating cash inflow more than doubled, pointing to accelerating global adoption of PhotonAssay and robust mining assay demand. The read-through is constructive for broader mining activity and metals services.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+2.07%
AI Insight · NCCOGOLD2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
ASX-listed Chrysos Corporation (C79) reported record earnings for FY26, with revenue, EBITDA and sample throughput all reaching new highs. Total revenue rose 33% year on year to US$88.1 million, while EBITDA jumped 68% to US$27.2 million, both landing at the top end of prior guidance. EBITDA margin improved to 31% from 24%.
Sample throughput climbed 67% to 11.3 million, and net operating cash inflow more than doubled, up 103% to US$17.9 million. The company attributed the strong performance to accelerating global adoption of its PhotonAssay technology, pointing to robust demand for mining assay services.
